Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform
Zomedica announced the launch of Over-the-Air (OTA) software and firmware update capabilities for its TRUFORMA diagnostic platform on May 15, 2024. This enhancement enables rapid deployment of new assays and features, improving the customer experience. The OTA updates will be managed via Zomedica's myZomedica cloud and IoT platform, allowing customers to apply updates with a single button push. This update follows Zomedica's acquisition of Qorvo Biotechnologies in 2023 and supports the expansion of the TRUFORMA product line. The company aims to streamline the update process and reduce barriers for customer adoption of new assays, while enhancing existing ones and freeing up sales staff from manual upgrade tasks.
- Launch of OTA update capabilities for TRUFORMA platform on May 15, 2024.
- Enables rapid deployment of new assays and features.
- OTA updates managed via myZomedica cloud and IoT platform.
- Customers can apply updates with a single button push.
- Supports expansion of TRUFORMA product line after Qorvo Biotechnologies acquisition in 2023.
- Streamlines update process, reducing barriers for customer adoption.
- Enhances existing assays and reduces manual upgrade tasks for sales staff.
- No direct financial data or projections provided.
- Potential technical issues with OTA updates not addressed.
- Implementation costs for OTA capabilities not disclosed.
Insights
Zomedica's introduction of Over-the-Air (OTA) software update capabilities for its TRUFORMA(R) platform is a significant advancement in the veterinary diagnostics industry. OTA updates are a common feature in many tech devices today, from smartphones to automotive systems, allowing companies to release improvements and fixes remotely without requiring physical service interventions.
This move positions Zomedica favorably in terms of scalability and customer convenience. By enabling updates through the myZomedica cloud platform, they ensure that any new assays or features can be rapidly deployed, enhancing the functionality and performance of the TRUFORMA system. This can potentially reduce downtime for veterinary practices as they will no longer need to wait for manual updates or service visits.
Moreover, this capability underscores Zomedica's commitment to leveraging modern Internet-of-Things (IoT) solutions, which could be a strategic differentiator in the competitive veterinary diagnostics market. It will likely enhance user satisfaction by making the TRUFORMA platform more adaptable and future-proof.
The introduction of OTA update capabilities for the TRUFORMA platform could have notable market implications for Zomedica. This technological enhancement can significantly improve customer retention and acquisition. By offering a seamless way to keep their diagnostic tools up-to-date, Zomedica can reduce operational friction for veterinary practices, making their products more attractive compared to competitors who may still rely on traditional update methods.
Furthermore, this development could lead to an increase in recurring revenue streams. As new assays and features are introduced and made swiftly available through OTA updates, customers might be more inclined to invest in ongoing service subscriptions or other related products, thereby driving revenue growth.
However, it's important to consider potential challenges such as cybersecurity risks associated with OTA updates. Ensuring the resilience and security of these updates will be important to maintaining customer trust and protecting sensitive data within the veterinary practices that use TRUFORMA.
OTA capability enhances introduction of new assays from rapidly expanding menu
ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of Over-the-Air ("OTA") software and firmware update capabilities for its TRUFORMA point-of-care diagnostic platform.
"We recognized the need to deliver software and firmware updates remotely early in the TRUFORMA development," said Evan St. Peter, Vice President of Technology Innovation at Zomedica. "Following our 2023 acquisition of Qorvo Biotechnologies and the growth of the TRUFORMA product line with recent assay launches, the timing for adding this capability is ideal. We're excited to harness OTA updates to enable rapid deployment of new assays and deliver new features and customer experiences on the TRUFORMA platform."
OTA updates will be delivered via Zomedica's myZomedica® cloud customer experience and Internet-of-Things (IoT) platform. OTA capabilities streamline the software update process for both Zomedica and its customers. When a new software update is available, customers will be notified on their device and can apply the update with the push of a button. The myZomedica global OTA service includes best practices capabilities for staged deployments to ensure software update resiliency.
"The release of TRUFORMA OTA software update capabilities demonstrates Zomedica's dedication to accelerating delivery of highly beneficial assays on the TRUFORMA diagnostic platform," said Larry Heaton, Chief Executive Officer of Zomedica. "These capabilities further reduce barriers for customer adoption of newly launched assays, provide an efficient means of delivering timely enhancements for existing assays, and free up our salespeople from performing manual upgrades."
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- X (formerly Twitter): https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the significance of Zomedica's OTA update capability launch?
How will Zomedica's OTA updates be delivered?
What is the impact of the OTA update capability on Zomedica's TRUFORMA product line?
What was a key factor in the timing of Zomedica's OTA capability launch?
How will OTA capabilities benefit Zomedica's sales staff?
